Artiva Biotherapeutics, Inc.

$7.05Close · Oct 7, 2026

News

Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren’s Disease
Sep 23, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Sep 17, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026
Sep 8, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September
Sep 2, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Aug 6, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Jun 23, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
Jun 8, 2026Artiva Biotherapeutics, Inc. Press Releases
Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 28, 2026Artiva Biotherapeutics, Inc. Press Releases
SDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy
May 26, 2026Artiva Biotherapeutics
Artiva was featured in San Diego Business Journal following its $300 million financing to support the continued advancement of AlloNK® in autoimmune disease. The article discusses the company’s planned Phase 3 trial in refractory rheumatoid arthritis and its focus on developing an outpatient-ready, scalable approach to deep B-cell depletion. Read the article here (subscription may... The post SDBJ: Artiva Raises $300M to Fund Phase 3 Trial for RA Cell Therapy appeared first on Artiva Biotherapeutics.